In contrast, LAG-3 monoclonal antibody can restore the body’s anti-tumor immune activity by reducing the number of bone marrow-derived suppressor cells (MDSC), inhibiting the activity of Treg cells in the tumor microenvironment and increasing the number of activated CD8+ T cells (93). This evidence concerns the gene CD8A and neoplasm.